Merck, Nimbus, and Other Big Pharma Companies Face Increased Pressure for Platform Technology and Due Diligence Before Deal Closures
Big Pharma's Invisible Due Diligence Barrier
With prolonged high-interest rates, multinational pharmaceutical companies like Merck are intensifying their pre-deal due diligence on biotech companies. Unlike the past, partnerships now require not only promising substances but also demonstrable reproducibility of clinical data. Merck's Boston Innovation Hub, for example, thoroughly verifies the mechanism of action of substances from early stages. This rigorous pre-verification is a change stemming from big pharma's risk management strategy to minimize failure costs.
Platform Biotech's Ruthless Pipeline Management
Platform companies like Nimbus Therapeutics and Hyku Biosciences are facing pressure to prioritize and focus their efforts amid fundraising challenges. Abbas Kazemi, CEO of Nimbus, demonstrates a disciplined approach by maintaining an internal attrition rate of 75-80%, quickly eliminating unpromising assets. This is a survival strategy to efficiently deploy limited capital, gain investor trust, and maximize value. Making swift decisions to discard high-risk candidate substances, rather than pursuing unconditional expansion, is becoming a key indicator of corporate value.
Strategic Licensing Deals in the Obesity Treatment Market
The recent co-development agreement between Eli Lilly and Nimbus for oral treatments for obesity and metabolic diseases is a successful example of this verification process. The deal is worth a total of $1.3 billion, including an upfront payment and short-term milestones of $55 million, demonstrating the proven capabilities of Nimbus's drug design platform. Nimbus secured the deal with Lilly by highlighting its unique allosteric modulation mechanism. With the global obesity market expected to grow rapidly to $100 billion by 2030, this demonstrates that differentiated platform technology is the key to entering this large market.
The Rise of Chinese Biotech and Changes in Technology In-licensing Strategies
The value of Chinese biotech pipelines is rapidly increasing, leading to diversification in big pharma's technology in-licensing strategies. In the past, Chinese assets were an alternative that could be acquired at a low price, but recent deal sizes have more than doubled, making it no longer a market where low-cost acquisitions are possible. As a result, big pharma companies are building systems to leverage AI platforms and local networks to identify and verify undervalued early-stage substances. This is a trend where multinational pharmaceutical companies are internalizing local expertise to maintain price negotiation power in global technology transactions and reduce development failure rates.
In the context of a global high-interest rate environment, thorough pre-deal due diligence and rigorous pipeline management for early-stage substances entering Phase 1/2 clinical trials are critical for the survival of platform biotech companies. Nimbus's agreement with Eli Lilly, with an upfront payment of $55 million and a total value of $1.3 billion for an obesity treatment, demonstrates the value of a differentiated allosteric platform compared to competitors like Novo Nordisk in a market expected to grow to $100 billion by 2030. The strengthening of due diligence by big pharma companies like Merck is a factor that short-term reduces the proportion of upfront payments in deal terms and shifts the transaction structure towards performance-based milestones. In the medium to long term, Nimbus's self-regulatory approach, maintaining a high internal attrition rate of 75-80%, will become an industry standard that improves the success rate of venture capital fund recovery. Furthermore, with the price of Chinese pipelines more than doubling, big pharma companies will focus on building systems for proactive identification and enhanced due diligence of early-stage substances through AI and local networks.
Source: FierceBiotech (rss)